Multi-omics for biomarker approaches in the diagnostic evaluation and management of abdominal pain and irritable bowel syndrome: what lies ahead

References

• Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study. Gastroenterology. 2021;160:99–114 e3. doi:10.1053/j.gastro.2020.04.014.
   PubMed Web of Science ®Google Scholar
• Tornkvist NT, Aziz I, Whitehead WE, Sperber AD, Palsson OS, Hreinsson JP, Simrén M, Törnblom H. Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European Gastroenterol J. 2021;9:1178–25. doi:10.1002/ueg2.12153.
   PubMed Web of Science ®Google Scholar
• Peery AF, Crockett SD, Murphy CC, Jensen ET, Kim HP, Egberg MD, Lund JL, Moon AM, Pate V, Barnes EL, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021. Gastroenterology. 2022;162:621–644. doi:10.1053/j.gastro.2021.10.017.
   PubMed Web of Science ®Google Scholar
• Goodoory VC, Ng CE, Black CJ, Ford AC. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022;56:110–120. doi:10.1111/apt.16939.
   PubMed Web of Science ®Google Scholar
• Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. 2013;19:755–764. doi:10.18553/jmcp.2013.19.9.755.
   PubMed Web of Science ®Google Scholar
• Zhang F, Xiang W, Li CY, Li S-C. Economic burden of irritable bowel syndrome in China. World J Gastroenterol. 2016;22:10450–10460. doi:10.3748/wjg.v22.i47.10450.
   PubMed Web of Science ®Google Scholar
• Ballou S, McMahon C, Lee HN, Katon J, Shin A, Rangan V, Singh P, Nee J, Camilleri M, Lembo A, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey. Clin Gastroenterol Hepatol. 2019;17:2471–2478 e3. doi:10.1016/j.cgh.2019.08.016.
   PubMed Web of Science ®Google Scholar
• Frandemark A, Tornblom H, Jakobsson S, Simrén M. Work Productivity And Activity Impairment In Irritable Bowel Syndrome (IBS): a Multifaceted problem. Am J Gastroenterol. 2018;113:1540–1549. doi:10.1038/s41395-018-0262-x.
   PubMed Web of Science ®Google Scholar
• Akehurst RL, Brazier JE, Mathers N, O??keefe C, Kaltenthaler E, Morgan A, Platts M, Walters SJ. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002;20:455–462. doi:10.2165/00019053-200220070-00003.
   PubMed Web of Science ®Google Scholar
• Amouretti M, Le Pen C, Gaudin AF, Bommelaer G, Frexinos J, Ruszniewski P, Poynard T, Maurel F, Priol G, El Hasnaoui A. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroentérologie Clinique et Biologique. 2006;30:241–246. doi:10.1016/S0399-8320(06)73160-8.
   PubMedGoogle Scholar
• Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–660. doi:10.1053/gast.2000.16484.
   PubMed Web of Science ®Google Scholar
• Wang YT, Lim HY, Tai D, Krishnamoorthy TL, Tan T, Barbier S, Thumboo J. The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol. 2012;12:104. doi:10.1186/1471-230X-12-104.
   PubMed Web of Science ®Google Scholar
• Chang L, Di Lorenzo C, Farrugia G, Hamilton FA, Mawe GM, Pasricha PJ, Wiley JW. Functional bowel disorders: a roadmap to guide the next generation of research. Gastroenterology. 2018;154:723–735. doi:10.1053/j.gastro.2017.12.010.
   PubMed Web of Science ®Google Scholar
• (CDER). USDoHaHSFaDACfDEaR. Guidance for industry: Irritable bowel syndrome—clinical evaluation of drugs for treatment, 2012.
   Google Scholar
• Lacy BE, Chey WD, Lembo AJ. New and emerging treatment options for irritable bowel syndrome. Gastroenterol Hepatol (N Y). 2015;11:1–19.
   PubMedGoogle Scholar
• Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396:1675–1688. doi:10.1016/S0140-6736(20)31548-8.
   PubMed Web of Science ®Google Scholar
• Smalley W, Falck-Ytter C, Carrasco-Labra A, Wani S, Lytvyn L, Falck-Ytter Y. AGA clinical practice guidelines on the laboratory evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D). Gastroenterology. 2019;157:851–854. doi:10.1053/j.gastro.2019.07.004.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116:17–44. doi:10.14309/ajg.0000000000001036.
   PubMed Web of Science ®Google Scholar
• Rangan V, Ballou S, Shin A, Camilleri M, Lembo A, Nee J, Iturrino J, Singh P, Patel R. Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America Survey. Gastroenterology. 2020;158:786–788 e1. doi:10.1053/j.gastro.2019.10.036.
   PubMed Web of Science ®Google Scholar
• Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, Surawicz CM, Chey WD. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D). Gastroenterology. 2019;157:859–880. doi:10.1053/j.gastro.2019.06.014.
   PubMed Web of Science ®Google Scholar
• Simren M, Tornblom H, Palsson OS, van Tilburg MAL, Van Oudenhove L, Tack J, Whitehead WE. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. Gut. 2018;67:255–262. doi:10.1136/gutjnl-2016-312361.
   PubMed Web of Science ®Google Scholar
• Simren M, Tornblom H, Palsson OS, Van Oudenhove L, Whitehead WE, Tack J. Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology. 2019;157:391–402 e2. doi:10.1053/j.gastro.2019.04.019.
   PubMed Web of Science ®Google Scholar
• Yu V, Ballou S, Hassan R, Singh P, Shah E, Rangan V, Iturrino J, Nee J, Lembo A. Abdominal pain and depression, not bowel habits, predict health care utilization in patients with functional bowel disorders. Am J Gastroenterol. 2021;116:1720–1726. doi:10.14309/ajg.0000000000001306.
   PubMed Web of Science ®Google Scholar
• Sobsey CA, Ibrahim S, Richard VR, Gaspar V, Mitsa G, Lacasse V, Zahedi RP, Batist G, Borchers CH. Targeted and untargeted proteomics approaches in biomarker development. Proteomics. 2020;20:e1900029. doi:10.1002/pmic.201900029.
   PubMed Web of Science ®Google Scholar
• Clarke G, Quigley EM, Cryan JF, Dinan TG. Irritable bowel syndrome: towards biomarker identification. Trends Mol Med. 2009;15:478–489. doi:10.1016/j.molmed.2009.08.001.
   PubMed Web of Science ®Google Scholar
• Knowles CH, Aziz Q. Basic and clinical aspects of gastrointestinal pain. Pain. 2009;141:191–209. doi:10.1016/j.pain.2008.12.011.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Genetics of human gastrointestinal sensation. Neurogastroenterol Motil. 2013;25:458–466. doi:10.1111/nmo.12132.
   PubMed Web of Science ®Google Scholar
• Johnson AC, Farmer AD, Ness TJ, Greenwood‐van Meerveld B. Critical evaluation of animal models of visceral pain for therapeutics development: a focus on irritable bowel syndrome. Neurogastroenterol Motil. 2020;32:e13776. doi:10.1111/nmo.13776.
   PubMed Web of Science ®Google Scholar
• Dinan TG, Cryan JF. The microbiome-gut-brain axis in health and disease. Gastroenterol Clin North Am. 2017;46:77–89. doi:10.1016/j.gtc.2016.09.007.
   PubMed Web of Science ®Google Scholar
• Esquerre N, Basso L, Dubuquoy C, Djouina M, Chappard D, Blanpied C, Desreumaux P, Vergnolle N, Vignal C, Body-Malapel M. Aluminum ingestion promotes colorectal hypersensitivity in rodents. Cell Mol Gastroenterol Hepatol. 2019;7:185–196. doi:10.1016/j.jcmgh.2018.09.012.
   PubMed Web of Science ®Google Scholar
• De Palma G, Shimbori C, Reed DE, Yu Y, Rabbia V, Lu J, Jimenez-Vargas N, Sessenwein J, Lopez-Lopez C, Pigrau M, et al. Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice. Sci Transl Med. 2022;14:eabj1895. doi:10.1126/scitranslmed.abj1895.
   PubMed Web of Science ®Google Scholar
• Aguilera-Lizarraga J, Florens MV, Viola MF, Jain P, Decraecker L, Appeltans I, Cuende-Estevez M, Fabre N, Van Beek K, Perna E, et al. Local immune response to food antigens drives meal-induced abdominal pain. Nature. 2021;590:151–156. doi:10.1038/s41586-020-03118-2.
   PubMed Web of Science ®Google Scholar
• Grabauskas G, Wu X, Gao J, Li J-Y, Turgeon DK, Owyang C. Prostaglandin E2, produced by mast cells in colon tissues from patients with irritable bowel syndrome, contributes to visceral hypersensitivity in mice. Gastroenterology. 2020;158:2195–2207 e6. doi:10.1053/j.gastro.2020.02.022.
   PubMed Web of Science ®Google Scholar
• Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59:1213–1221. doi:10.1136/gut.2010.213108.
   PubMed Web of Science ®Google Scholar
• Wouters MM, Balemans D, Van Wanrooy S, Dooley J, Cibert-Goton V, Alpizar YA, Valdez-Morales EE, Nasser Y, Van Veldhoven PP, Vanbrabant W, et al. Histamine receptor H1–Mediated Sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016;150:875–87 e9. doi:10.1053/j.gastro.2015.12.034.
   PubMed Web of Science ®Google Scholar
• Long Y, Du L, Kim JJ, Chen B, Zhu Y, Zhang Y, Yao S, He H, Zheng X, Huang Z, et al. MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice. Neurogastroenterol Motil. 2018;30:e13348. doi:10.1111/nmo.13348.
   PubMed Web of Science ®Google Scholar
• Wiley JW, Zong Y, Zheng G, Zhu S, Hong S. Histone H3K9 methylation regulates chronic stress and IL-6–induced colon epithelial permeability and visceral pain. Neurogastroenterol Motil. 2020;32:e13941. doi:10.1111/nmo.13941.
   PubMed Web of Science ®Google Scholar
• Hanning N, Edwinson AL, Ceuleers H, Peters SA, De Man JG, Hassett LC, De Winter BY, Grover M. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586. doi:10.1177/1756284821993586.
   Web of Science ®Google Scholar
• Perna E, Aguilera-Lizarraga J, Florens MV, Jain P, Theofanous SA, Hanning N, De Man JG, Berg M, De Winter B, Alpizar YA, et al. Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS. Gut. 2021;70:1275–1286. doi:10.1136/gutjnl-2020-321530.
   PubMed Web of Science ®Google Scholar
• Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology. 2007;132:615–627. doi:10.1053/j.gastro.2006.11.014.
   PubMed Web of Science ®Google Scholar
• Castro J, Harrington AM, Garcia-Caraballo S, Maddern J, Grundy L, Zhang J, Page G, Miller PE, Craik DJ, Adams DJ, et al. α-Conotoxin Vc1.1 inhibits human dorsal root ganglion neuroexcitability and mouse colonic nociception via GABA B receptors. Gut. 2017;66:1083–1094. doi:10.1136/gutjnl-2015-310971.
   PubMed Web of Science ®Google Scholar
• Osteen JD, Herzig V, Gilchrist J, Emrick JJ, Zhang C, Wang X, Castro J, Garcia-Caraballo S, Grundy L, Rychkov GY, et al. Selective spider toxins reveal a role for the Nav1.1 channel in mechanical pain. Nature. 2016;534:494–499. doi:10.1038/nature17976.
   PubMed Web of Science ®Google Scholar
• Peiris M, Weerts Z, Aktar R, Masclee AAM, Blackshaw A, Keszthelyi D. A putative anti-inflammatory role for TRPM8 in irritable bowel syndrome—an exploratory study. Neurogastroenterol Motil. 2021;33:e14170. doi:10.1111/nmo.14170.
   PubMed Web of Science ®Google Scholar
• Akbar A, Yiangou Y, Facer P, Walters JRF, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57:923–929. doi:10.1136/gut.2007.138982.
   PubMed Web of Science ®Google Scholar
• Grover M, Berumen A, Peters S, Wei T, Breen‐lyles M, Harmsen WS, Busciglio I, Burton D, Vazquez Roque M, DeVault KR, et al. Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression. Aliment Pharmacol Ther. 2021;54:1179–1192. doi:10.1111/apt.16591.
   PubMed Web of Science ®Google Scholar
• Cenac N, Bautzova T, Le Faouder P, Veldhuis NA, Poole DP, Rolland C, Bertrand J, Liedtke W, Dubourdeau M, Bertrand-Michel J, et al. Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome. Gastroenterology. 2015;149:433–44 e7. doi:10.1053/j.gastro.2015.04.011.
   PubMed Web of Science ®Google Scholar
• Locke GR 3rd, Ackerman MJ, Zinsmeister AR, Thapa P, Farrugia G. Gastrointestinal symptoms in families of patients with an SCN5A-encoded cardiac channelopathy: evidence of an intestinal channelopathy. Am J Gastroenterol. 2006;101:1299–1304. doi:10.1111/j.1572-0241.2006.00507.x.
   PubMed Web of Science ®Google Scholar
• Long X, Li M, Li LX, Sun Y-Y, Zhang W-X, Zhao D-Y, Li Y-Q. Butyrate promotes visceral hypersensitivity in an IBS-like model via enteric glial cell-derived nerve growth factor. Neurogastroenterol Motil. 2018;30:e13227. doi:10.1111/nmo.13227.
   PubMed Web of Science ®Google Scholar
• Bourdu S, Dapoigny M, Chapuy E, Artigue F, Vasson M-P, Dechelotte P, Bommelaer G, Eschalier A, Ardid D. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology. 2005;128:1996–2008. doi:10.1053/j.gastro.2005.03.082.
   PubMed Web of Science ®Google Scholar
• Vanhoutvin SA, Troost FJ, Kilkens TO, Lindsey PJ, Hamer HM, Jonkers DMAE, Venema K, Brummer RJM. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil. 2009;21:952–e76. doi:10.1111/j.1365-2982.2009.01324.x.
   PubMed Web of Science ®Google Scholar
• Wang P, Du C, Chen FX, Li C-Q, Yu Y-B, Han T, Akhtar S, Zuo X-L, Tan X-D, Li Y-Q. BDNF contributes to IBS-like colonic hypersensitivity via activating the enteroglia-nerve unit. Sci Rep. 2016;6:20320. doi:10.1038/srep20320.
   PubMed Web of Science ®Google Scholar
• Liang WJ, Zhang G, Luo HS, Liang L-X, Huang D, Zhang F-C. Tryptase and protease-activated receptor 2 expression levels in irritable bowel syndrome. Gut Liver. 2016;10:382–390. doi:10.5009/gnl14319.
   PubMed Web of Science ®Google Scholar
• Brierley SM, Greenwood-Van Meerveld B, Sarnelli G, Sharkey KA, Storr M, Tack J. Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome. Nat Rev Gastroenterol Hepatol. 2022. doi:10.1038/s41575-022-00682-y.
   PubMed Web of Science ®Google Scholar
• Cremon C, Stanghellini V, Barbaro MR, Cogliandro RF, Bellacosa L, Santos J, Vicario M, Pigrau M, Alonso Cotoner C, Lobo B, et al. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Ther. 2017;45:909–922. doi:10.1111/apt.13958.
   PubMed Web of Science ®Google Scholar
• Crouzet L, Gaultier E, Del’homme C, Cartier C, Delmas E, Dapoigny M, Fioramonti J, Bernalier-Donadille A. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil. 2013;25:e272–82. doi:10.1111/nmo.12103.
   PubMed Web of Science ®Google Scholar
• Li YJ, Li J, Dai C. The role of intestinal microbiota and mast cell in a rat model of visceral hypersensitivity. J Neurogastroenterol Motil. 2020;26:529–538. doi:10.5056/jnm20004.
   PubMed Web of Science ®Google Scholar
• Xu D, Gao J, Gillilland M 3rd, Wu X, Song I, Kao JY, Owyang C. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146:484–96 e4. doi:10.1053/j.gastro.2013.10.026.
   PubMed Web of Science ®Google Scholar
• Choo C, Mahurkar-Joshi S, Dong TS, Lenhart A, Lagishetty V, Jacobs JP, Labus JS, Jaffe N, Mayer EA, Chang L. Colonic mucosal microbiota is associated with bowel habit subtype and abdominal pain in patients with irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2022;323:G134–143. doi:10.1152/ajpgi.00352.2021.
   PubMed Web of Science ®Google Scholar
• Pozuelo M, Panda S, Santiago A, Mendez S, Accarino A, Santos J, Guarner F, Azpiroz F, Manichanh C. Reduction of butyrate- and methane-producing microorganisms in patients With irritable bowel syndrome. Sci Rep. 2015;5:12693. doi:10.1038/srep12693.
   PubMed Web of Science ®Google Scholar
• Holvoet T, Joossens M, Vazquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, Verhasselt B, van Vlierberghe H, De Vos M, Raes J, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology. 2021;160:145–157 e8. doi:10.1053/j.gastro.2020.07.013.
   PubMed Web of Science ®Google Scholar
• Louwies T, Orock A, Greenwood-Van Meerveld B. Stress-induced visceral pain in female rats is associated with epigenetic remodeling in the central nucleus of the amygdala. Neurobiol Stress. 2021;15:100386.
   PubMed Web of Science ®Google Scholar
• Yuan T, Manohar K, Latorre R, Orock A, Greenwood-Van Meerveld B. Inhibition of microglial activation in the amygdala reverses stress-induced abdominal pain in the male rat. Cell Mol Gastroenterol Hepatol. 2020;10:527–543. doi:10.1016/j.jcmgh.2020.04.020.
   PubMed Web of Science ®Google Scholar
• Videlock EJ, Shih W, Adeyemo M, Mahurkar-Joshi, S, Presson, AP, Polytarchou, C, Alberto, M, Iliopoulos, D, Mayer, EA, Chang, L, et al. The effect of sex and irritable bowel syndrome on HPA axis response and peripheral glucocorticoid receptor expression. Psychoneuroendocrinology. 2016;69:67–76. doi:10.1016/j.psyneuen.2016.03.016.
   PubMed Web of Science ®Google Scholar
• Du L, Long Y, Kim JJ, Chen B, Zhu Y, Dai N. Protease activated receptor-2 induces immune activation and visceral hypersensitivity in post-infectious irritable bowel syndrome mice. Dig Dis Sci. 2019;64:729–739. doi:10.1007/s10620-018-5367-y.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Yang WR, Wang XH, Li G-Q, Xu L-Q, Cui X, Liu Y, Zuo X-L. Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells. World J Gastroenterol. 2019;25:5469–5482. doi:10.3748/wjg.v25.i36.5469.
   PubMed Web of Science ®Google Scholar
• Yang J, Shang B, Shi H, Zhu S, Lu G, Dai F. The role of toll-like receptor 4 and mast cell in the ameliorating effect of electroacupuncture on visceral hypersensitivity in rats. Neurogastroenterol Motil. 2019;31:e13583. doi:10.1111/nmo.13583.
   PubMed Web of Science ®Google Scholar
• Feng B, La JH, Schwartz ES, Gebhart GF. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1085–98. doi:10.1152/ajpgi.00542.2011.
   PubMed Web of Science ®Google Scholar
• Shimbori C, De Palma G, Baerg L, Lu J, Verdu EF, Reed DE, Vanner S, Collins SM, Bercik P. Gut bacteria interact directly with colonic mast cells in a humanized mouse model of IBS. Gut Microbes. 2022;14:2105095. doi:10.1080/19490976.2022.2105095.
   PubMed Web of Science ®Google Scholar
• Li WT, Luo QQ, Wang B, Chen X, Yan X-J, Qiu H-Y, Chen S-L. Bile acids induce visceral hypersensitivity via mucosal mast cell–to–nociceptor signaling that involves the farnesoid X receptor/nerve growth factor/transient receptor potential vanilloid 1 axis. Faseb J. 2019;33:2435–2450. doi:10.1096/fj.201800935RR.
   PubMed Web of Science ®Google Scholar
• Gong L, Li J, Tang Y, Han T, Wei C, Yu X, Li J, Wang R, Ma X, Liu K, et al. The antinociception of oxytocin on colonic hypersensitivity in rats was mediated by inhibition of mast cell degranulation via Ca(2+)-NOS pathway. Sci Rep. 2016;6:31452. doi:10.1038/srep31452.
   PubMed Web of Science ®Google Scholar
• Xu X, Dong Q, Zhong Q, Xiu W, Chen Q, Wang J, Zhou Z. The flavonoid kurarinone regulates macrophage functions via aryl hydrocarbon receptor and alleviates intestinal inflammation in irritable bowel syndrome. J Inflamm Res. 2021;14:4347–4359. doi:10.2147/JIR.S329091.
   PubMed Web of Science ®Google Scholar
• Ren YJ, Zhang L, Bai T, Yu H-L, Li Y, Qian W, Jin S, Xiong Z-F, Wang H, Hou X-H. Transfer of CD11c+ lamina propria mononuclear phagocytes from post-infectious irritable bowel syndrome causes mucosal barrier dysfunction and visceral hypersensitivity in recipient mice. Int J Mol Med. 2017;39:1555–1563. doi:10.3892/ijmm.2017.2966.
   PubMed Web of Science ®Google Scholar
• Maeva M, Elodie B, Nathalie R, Defaye M, Straube M, Daugey V, Modoux M, Wawrzyniak I, Delbac F, Villéger R, et al. AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms. Gut Microbes. 2022;14:2022997. doi:10.1080/19490976.2021.2022997.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang L, Lu B, Chen Z, Chu L, Meng L, Fan Y. Role of dendritic cell-mediated abnormal immune response in visceral hypersensitivity. Int J Clin Exp Med. 2015;8:13243–13250.
   PubMed Web of Science ®Google Scholar
• Cardoso FC, Castro J, Grundy L, Schober G, Garcia-Caraballo S, Zhao T, Herzig V, King GF, Brierley SM, Lewis RJ. A spider-venom peptide with multitarget activity on sodium and calcium channels alleviates chronic visceral pain in a model of irritable bowel syndrome. Pain. 2021;162:569–581. doi:10.1097/j.pain.0000000000002041.
   PubMed Web of Science ®Google Scholar
• Salvatierra J, Castro J, Erickson A, Li Q, Braz J, Gilchrist J, Grundy L, Rychkov GY, Deiteren A, Rais R, et al. NaV1.1 inhibition can reduce visceral hypersensitivity. JCI Insight. 2018;3. doi:10.1172/jci.insight.121000.
   PubMed Web of Science ®Google Scholar
• Scanzi J, Accarie A, Muller E, Pereira B, Aissouni Y, Goutte M, Joubert-Zakeyh J, Picard E, Boudieu L, Mallet C, et al. Colonic overexpression of the T-type calcium channel Cav 3.2 in a mouse model of visceral hypersensitivity and in irritable bowel syndrome patients. Neurogastroenterol Motil. 2016;28:1632–1640. doi:10.1111/nmo.12860.
   PubMed Web of Science ®Google Scholar
• Bai T, Li Y, Xia J, Jiang Y, Zhang L, Wang H, Qian W, Song J, Hou X. Piezo2: a candidate biomarker for visceral hypersensitivity in irritable bowel syndrome? J Neurogastroenterol Motil. 2017;23:453–463. doi:10.5056/jnm16114.
   PubMed Web of Science ®Google Scholar
• Hughes PA, Harrington AM, Castro J, Liebregts T, Adam B, Grasby DJ, Isaacs NJ, Maldeniya L, Martin CM, Persson J, et al. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut. 2013;62:1456–1465. doi:10.1136/gutjnl-2011-301856.
   PubMed Web of Science ®Google Scholar
• Brierley SM, Hughes PA, Page AJ, Kwan KY, Martin CM, O’Donnell TA, Cooper NJ, Harrington AM, Adam B, Liebregts T, et al. The ion channel TRPA1 is required for normal mechanosensation and is modulated by algesic stimuli. Gastroenterology. 2009;137:2084–2095 e3. doi:10.1053/j.gastro.2009.07.048.
   PubMed Web of Science ®Google Scholar
• Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats. J Gastroenterol. 2017;52:72–80. doi:10.1007/s00535-016-1208-y.
   PubMed Web of Science ®Google Scholar
• Gao J, Xiong T, Grabauskas G, Owyang C. Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via mast cell–prostaglandin E2. Gastroenterology. 2022;162:1962–1974 e6. doi:10.1053/j.gastro.2022.02.016.
   PubMed Web of Science ®Google Scholar
• Grabauskas G, Gao J, Wu X, Zhou, SY, Turgeon, DK, Owyang, C, et al. Gut Microbiota Alter Visceral Pain Sensation and Inflammation via Modulation of Synthesis of Resolvin D1 in Colonic Tuft Cells. Gastroenterology. 2022. doi:10.1053/j.gastro.2022.07.053.
   Google Scholar
• Matsumoto K, Takata K, Yamada D, Usuda H, Wada K, Tada M, Mishima Y, Ishihara S, Horie S, Saitoh A, et al. Juvenile social defeat stress exposure favors in later onset of irritable bowel syndrome-like symptoms in male mice. Sci Rep. 2021;11:16276. doi:10.1038/s41598-021-95916-5.
   PubMed Web of Science ®Google Scholar
• El-Ayache N, Galligan JJ. 5-HT3 receptor signaling in serotonin transporter-knockout rats: a female sex-specific animal model of visceral hypersensitivity. Am J Physiol Gastrointest Liver Physiol. 2019;316:G132–143. doi:10.1152/ajpgi.00131.2018.
   PubMed Web of Science ®Google Scholar
• Liao XJ, Mao WM, Wang Q, Yang G-G, Wu W-J, Shao S-X. MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome. Biochem Biophys Res Commun. 2016;469:288–293. doi:10.1016/j.bbrc.2015.11.102.
   PubMed Web of Science ®Google Scholar
• Sun H, Ma Y, An S, Wang Z. Altered gene expression signatures by calcitonin gene-related peptide promoted mast cell activity in the colon of stress-induced visceral hyperalgesia mice. Neurogastroenterol Motil. 2021;33:e14073. doi:10.1111/nmo.14073.
   PubMed Web of Science ®Google Scholar
• Gilet M, Eutamene H, Han H, Kim, HW, Bueno, L, et al. Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation. Neurogastroenterol Motil. 2014;26:1761–1770.
   PubMed Web of Science ®Google Scholar
• Zielinska M, Fichna J, Bashashati M, Habibi S, Sibaev A, Timmermans J-P, Storr M. G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain. Neurogastroenterol Motil. 2017;29. doi:10.1111/nmo.13025.
   PubMed Web of Science ®Google Scholar
• Rolland-Fourcade C, Denadai-Souza A, Cirillo C, Lopez C, Jaramillo JO, Desormeaux C, Cenac N, Motta J-P, Larauche M, Taché Y, et al. Epithelial expression and function of trypsin-3 in irritable bowel syndrome. Gut. 2017;66:1767–1778. doi:10.1136/gutjnl-2016-312094.
   PubMed Web of Science ®Google Scholar
• Jimenez-Vargas NN, Pattison LA, Zhao P, Lieu T, Latorre R, Jensen DD, Castro J, Aurelio L, Le GT, Flynn B, et al. Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome. Proc Natl Acad Sci U S A. 2018;115:E7438–7447. doi:10.1073/pnas.1721891115.
   PubMed Web of Science ®Google Scholar
• Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S, Hannig G, Mann E, et al. Linaclotide Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and Extracellular Cyclic Guanosine 3′,5′-Monophosphate. Gastroenterology. 2013;145: 1334-46 e1-11. doi:10.1053/j.gastro.2013.08.017.
   PubMed Web of Science ®Google Scholar
• Moloney RD, Johnson AC, O’mahony SM, Dinan TG, Greenwood-Van Meerveld B, Cryan JF. Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: relevance to Irritable Bowel Syndrome. CNS Neurosci Ther. 2016;22:102–117. doi:10.1111/cns.12490.
   PubMed Web of Science ®Google Scholar
• Bashashati M, Moossavi S, Cremon C, Barbaro MR, Moraveji S, Talmon G, Rezaei N, Hughes PA, Bian ZX, Choi CH, et al. Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2018:30. doi:10.1111/nmo.13192
   Google Scholar
• Robles A, Perez Ingles D, Myneedu K, Deoker A, Sarosiek I, Zuckerman MJ, Schmulson MJ, Bashashati M. Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2019;31:e13718. doi:10.1111/nmo.13718.
   PubMed Web of Science ®Google Scholar
• Braak B, Klooker TK, Wouters MM, Welting O, van der Loos CM, Stanisor OI, van Diest S, van den Wijngaard RM, Boeckxstaens GE. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol. 2012;107:715–726. doi:10.1038/ajg.2012.54.
   PubMed Web of Science ®Google Scholar
• Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie–Doyle S, Smith E, Drew P, Talley NJ, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–920. doi:10.1053/j.gastro.2007.01.046.
   PubMed Web of Science ®Google Scholar
• Shulman RJ, Jarrett ME, Cain KC, Broussard EK, Heitkemper MM. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J Gastroenterol. 2014;49:1467–1476. doi:10.1007/s00535-013-0919-6.
   PubMed Web of Science ®Google Scholar
• Clave P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34:432–442. doi:10.1111/j.1365-2036.2011.04730.x.
   PubMed Web of Science ®Google Scholar
• Saito YA, Almazar AE, Tilkes KE, Choung RS, Van Norstrand MD, Schleck CD, Zinsmeister AR, Talley NJ. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther. 2019;49:389–397. doi:10.1111/apt.15077.
   PubMed Web of Science ®Google Scholar
• Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second-generation 2 ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56:1218–1225. doi:10.1136/gut.2006.110858.
   PubMed Web of Science ®Google Scholar
• Mawe GM, Hoffman JM. Serotonin signalling in the gut–functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10:473–486. doi:10.1038/nrgastro.2013.105.
   PubMed Web of Science ®Google Scholar
• Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011;106:1290–1298. doi:10.1038/ajg.2011.86.
   PubMed Web of Science ®Google Scholar
• Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M. SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1053–60. doi:10.1152/ajpgi.00153.2011.
   PubMed Web of Science ®Google Scholar
• Thijssen AY, Mujagic Z, Jonkers DM, Ludidi S, Keszthelyi D, Hesselink MA, Clemens CHM, Conchillo JM, Kruimel JW, Masclee AAM. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther. 2016;43:272–282. doi:10.1111/apt.13459.
   PubMed Web of Science ®Google Scholar
• Quigley EM. Editorial: serotonin and irritable bowel syndrome–reconciling pharmacological effects with basic biology. Aliment Pharmacol Ther. 2016;43:644–646. doi:10.1111/apt.13501.
   PubMed Web of Science ®Google Scholar
• Labus JS, Osadchiy V, Hsiao EY, Tap J, Derrien M, Gupta A, Tillisch K, Le Nevé B, Grinsvall C, Ljungberg M, et al. Evidence for an association of gut microbial Clostridia with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis. Microbiome. 2019;7:45. doi:10.1186/s40168-019-0656-z.
   PubMed Web of Science ®Google Scholar
• Hadizadeh F, Bonfiglio F, Belheouane M, Vallier M, Sauer S, Bang C, Bujanda L, Andreasson A, Agreus L, Engstrand L, et al. Faecal microbiota composition associates with abdominal pain in the general population. Gut. 2018;67:778–779. doi:10.1136/gutjnl-2017-314792.
   PubMed Web of Science ®Google Scholar
• Jalanka-Tuovinen J, Salonen A, Nikkila J, Immonen O, Kekkonen R, Lahti L, Palva A, de Vos WM. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. Plos One. 2011;6:e23035. doi:10.1371/journal.pone.0023035.
   PubMed Web of Science ®Google Scholar
• Frost F, Kacprowski T, Ruhlemann MC, Franke A, Heinsen F-A, Völker U, Völzke H, Aghdassi AA, Mayerle J, Weiss FU, et al. Functional abdominal pain and discomfort (IBS) is not associated with faecal microbiota composition in the general population. Gut. 2019;68:1131–1133. doi:10.1136/gutjnl-2018-316502.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Busciglio I, Acosta A, Shin A, Carlson P, Burton D, Ryks M, Rhoten D, Lamsam J, Lueke A, et al. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol. 2014;109:1621–1630. doi:10.1038/ajg.2014.215.
   PubMed Web of Science ®Google Scholar
• Wei W, Wang HF, Zhang Y, Zhang Y-L, Niu B-Y, Yao S-K. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome. World J Gastroenterol. 2020;26:7153–7172. doi:10.3748/wjg.v26.i45.7153.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Carlson P, BouSaba J, McKinzie S, Vijayvargiya P, Magnus Y, Sannaa W, Wang XJ, Chedid V, Zheng T, et al. Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea. Gut. 2022;72:54–65. doi:10.1136/gutjnl-2022-327471.
   PubMed Web of Science ®Google Scholar
• Tap J, Storsrud S, Le Neve B, Cotillard A, Pons N, Doré J, Öhman L, Törnblom H, Derrien M, Simrén M. Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome. Microbiome. 2021;9:74. doi:10.1186/s40168-021-01018-9.
   PubMed Web of Science ®Google Scholar
• Labus JS, Hollister EB, Jacobs J, Kirbach K, Oezguen N, Gupta A, Acosta J, Luna RA, Aagaard K, Versalovic J, et al. Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome. Microbiome. 2017;5:49. doi:10.1186/s40168-017-0260-z.
   PubMed Web of Science ®Google Scholar
• Xu XJ, Zhang YL, Liu L, Pan L, Yao SK. Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study. Aliment Pharmacol Ther. 2017;45:100–114. doi:10.1111/apt.13848.
   PubMed Web of Science ®Google Scholar
• Icenhour A, Witt ST, Elsenbruch S, Lowén M, Engström M, Tillisch K, Mayer EA, Walter S. Brain functional connectivity is associated with visceral sensitivity in women with Irritable Bowel Syndrome. Neuroimage Clin. 2017;15:449–457. doi:10.1016/j.nicl.2017.06.001.
   PubMed Web of Science ®Google Scholar
• Mayer EA, Labus J, Aziz Q, Tracey I, Kilpatrick L, Elsenbruch S, Schweinhardt P, Van Oudenhove L, Borsook D. Role of brain imaging in disorders of brain–gut interaction: a Rome Working Team Report. Gut. 2019;68:1701–1715. doi:10.1136/gutjnl-2019-318308.
   PubMed Web of Science ®Google Scholar
• Bhatt RR, Gupta A, Labus JS, Zeltzer LK, Tsao JC, Shulman RJ, Tillisch K. Altered Brain Structure and Functional Connectivity and Its Relation to Pain Perception in Girls with Irritable Bowel Syndrome. Psychosom Med. 2019;81:146–154. doi:10.1097/PSY.0000000000000655.
   PubMed Web of Science ®Google Scholar
• Kano M, Dupont P, Aziz Q, Fukudo S. Understanding Neurogastroenterology from Neuroimaging Perspective: a Comprehensive Review of Functional and Structural Brain Imaging in Functional Gastrointestinal Disorders. J Neurogastroenterol Motil. 2018;24:512–527. doi:10.5056/jnm18072.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Schindler D, Lovblad K, Redmond, SM, Nirkko, A, et al. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut. 2004;53:1595–1601. doi:10.1136/gut.2003.028514.
   PubMed Web of Science ®Google Scholar
• Chang L, Sundaresh S, Elliott J, Anton PA, Baldi P, Licudine A, Mayer M, Vuong T, Hirano M, Naliboff BD, et al. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil. 2009;21:149–159. doi:10.1111/j.1365-2982.2008.01171.x.
   PubMed Web of Science ®Google Scholar
• Margolis KG, Cryan JF, Mayer EA. The Microbiota-Gut-Brain Axis: from Motility to Mood. Gastroenterology. 2021;160:1486–1501. doi:10.1053/j.gastro.2020.10.066.
   PubMed Web of Science ®Google Scholar
• Jacobs JP, Gupta A, Bhatt RR, Brawer J, Gao K, Tillisch K, Lagishetty V, Firth R, Gudleski GD, Ellingson BM, et al. Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome. 2021;9:236. doi:10.1186/s40168-021-01188-6.
   PubMed Web of Science ®Google Scholar
• Bhatt RR, Gupta A, Labus JS, Liu C, Vora PP, Stains J, Naliboff BD, Mayer EA. A neuropsychosocial signature predicts longitudinal symptom changes in women with irritable bowel syndrome. Mol Psychiatry. 2022;27:1774–1791. doi:10.1038/s41380-021-01375-9.
   PubMed Web of Science ®Google Scholar
• Mayer EA, Gupta A, Kilpatrick LA, Hong J-Y. Imaging brain mechanisms in chronic visceral pain. Pain. 2015;156 Suppl 1:S50–63. doi:10.1097/j.pain.0000000000000106.
   PubMed Web of Science ®Google Scholar
• Sclocco R, Beissner F, Bianciardi M, Polimeni, JR, Napadow, V, et al. Challenges and opportunities for brainstem neuroimaging with ultrahigh field MRI. Neuroimage. 2018;168:412–426. doi:10.1016/j.neuroimage.2017.02.052.
   PubMed Web of Science ®Google Scholar
• Mujagic Z, Keszthelyi D, Aziz Q, Reinisch W, Quetglas EG, De Leonardis F, Segerdahl M, Masclee AAM. Systematic review: instruments to assess abdominal pain in irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42:1064–1081. doi:10.1111/apt.13378.
   PubMed Web of Science ®Google Scholar
• Shin A, Preidis GA, Shulman R, Kashyap PC. The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders. Clin Gastroenterol Hepatol. 2019;17:256–274. doi:10.1016/j.cgh.2018.08.054.
   PubMed Web of Science ®Google Scholar
• Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut Microbiota in Patients with Irritable Bowel Syndrome—A Systematic Review. Gastroenterology. 2019;157:97–108. doi:10.1053/j.gastro.2019.03.049.
   PubMed Web of Science ®Google Scholar
• Mars RAT, Frith M, Kashyap PC. Functional Gastrointestinal Disorders and the Microbiome-What is the Best Strategy for Moving Microbiome-based Therapies for Functional Gastrointestinal Disorders into the Clinic? Gastroenterology. 2021;160:538–555. doi:10.1053/j.gastro.2020.10.058.
   PubMed Web of Science ®Google Scholar
• Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Doré J, Störsrud S, Le Nevé B, Öhman L, Simrén M. Identification of an Intestinal Microbiota Signature Associated with Severity of Irritable Bowel Syndrome. Gastroenterology. 2017;152:111–123 e8. doi:10.1053/j.gastro.2016.09.049.
   PubMed Web of Science ®Google Scholar
• Botschuijver S, Roeselers G, Levin E, Jonkers DM, Welting O, Heinsbroek SEM, de Weerd HH, Boekhout T, Fornai M, Masclee AA, et al. Intestinal Fungal Dysbiosis is Associated with Visceral Hypersensitivity in Patients with Irritable Bowel Syndrome and Rats. Gastroenterology. 2017;153:1026–1039. doi:10.1053/j.gastro.2017.06.004.
   PubMed Web of Science ®Google Scholar
• Hillestad EMR, van der Meeren A, Nagaraja BH, Bjørsvik BR, Haleem N, Benitez-Paez A, Sanz Y, Hausken T, Lied GA, Lundervold A, et al. Gut bless you: the microbiota-gut-brain axis in irritable bowel syndrome. World J Gastroenterol. 2022;28:412–431. doi:10.3748/wjg.v28.i4.412.
   PubMed Web of Science ®Google Scholar
• Coughlan S, Das A, O’herlihy E, Shanahan F, O’toole PW, Jeffery IB. The gut virome in Irritable Bowel Syndrome differs from that of controls. Gut Microbes. 2021;13:1–15. doi:10.1080/19490976.2021.1887719.
   PubMed Web of Science ®Google Scholar
• Mihindukulasuriya KA, Mars RAT, Johnson AJ, Ward T, Priya S, Lekatz HR, Kalari KR, Droit L, Zheng T, Blekhman R, et al. Multi-Omics Analyses Show Disease, Diet, and Transcriptome Interactions with the Virome. Gastroenterology. 2021;161:1194–1207 e8. doi:10.1053/j.gastro.2021.06.077.
   PubMed Web of Science ®Google Scholar
• Botschuijver S, van Diest SA, van Thiel IAM, Saia RS, Strik AS, Yu Z, Maria-Ferreira D, Welting O, Keszthelyi D, Jennings G, et al. Miltefosine treatment reduces visceral hypersensitivity in a rat model for irritable bowel syndrome via multiple mechanisms. Sci Rep. 2019;9:12530. doi:10.1038/s41598-019-49096-y.
   PubMed Web of Science ®Google Scholar
• McIntosh K, Reed DE, Schneider T, Dang F, Keshteli AH, De Palma G, Madsen K, Bercik P, Vanner S. Fodmaps alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66:1241–1251. doi:10.1136/gutjnl-2015-311339.
   PubMed Web of Science ®Google Scholar
• Balemans D, Aguilera-Lizarraga J, Florens MV, Jain P, Denadai-Souza A, Viola MF, Alpizar YA, Van Der Merwe S, Vanden Berghe P, Talavera K, et al. Histamine-mediated potentiation of transient receptor potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2019;316:G338–349. doi:10.1152/ajpgi.00116.2018.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamashita R, Kawashima J, Mori H, Kurokawa K, Fukuda S, Gotoh Y, Nakamura K, Hayashi T, Kasahara Y, et al. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. J Gastroenterol. 2022. doi:10.1007/s00535-022-01888-2.
   Web of Science ®Google Scholar
• Baranska A, Mujagic Z, Smolinska A, Dallinga JW, Jonkers DMAE, Tigchelaar EF, Dekens J, Zhernakova A, Ludwig T, Masclee AAM, et al. Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach. Aliment Pharmacol Ther. 2016;44:45–56. doi:10.1111/apt.13654.
   PubMed Web of Science ®Google Scholar
• Zhu S, Liu S, Li H, Zhang Z, Zhang Q, Chen L, Zhao Y, Chen Y, Gu J, Min L, et al. Identification of Gut Microbiota and Metabolites Signature in Patients with Irritable Bowel Syndrome. Front Cell Infect Microbiol. 2019;9:346. doi:10.3389/fcimb.2019.00346.
   PubMed Web of Science ®Google Scholar
• Mars RAT, Yang Y, Ward T, Houtti M, Priya S, Lekatz HR, Tang X, Sun Z, Kalari KR, Korem T, et al. Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome. Cell. 2020;182:1460–1473 e17. doi:10.1016/j.cell.2020.08.007.
   PubMed Web of Science ®Google Scholar
• Gargari G, Taverniti V, Gardana C, Cremon C, Canducci F, Pagano I, Barbaro MR, Bellacosa L, Castellazzi AM, Valsecchi C, et al. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. Environ Microbiol. 2018;20:3201–3213. doi:10.1111/1462-2920.14271.
   PubMed Web of Science ®Google Scholar
• Jeffery IB, Das A, O’herlihy E, Coughlan S, Cisek K, Moore M, Bradley F, Carty T, Pradhan M, Dwibedi C, et al. Differences in Fecal Microbiomes and Metabolomes of People with vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. Gastroenterology. 2020;158:1016–1028 e8. doi:10.1053/j.gastro.2019.11.301.
   PubMed Web of Science ®Google Scholar
• Vijayvargiya P, Camilleri M, Burton D, Busciglio I, Lueke A, Donato LJ. Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome. Aliment Pharmacol Ther. 2019;49:744–758. doi:10.1111/apt.15106.
   PubMed Web of Science ®Google Scholar
• Ahluwalia B, Iribarren C, Magnusson MK, Sundin J, Clevers E, Savolainen O, Ross AB, Törnblom H, Simrén M, Öhman L. A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome. Cells. 2021;10. doi:10.3390/cells10061459.
   PubMed Web of Science ®Google Scholar
• Kumar A, Misra BB. Challenges and Opportunities in Cancer Metabolomics. Proteomics. 2019;19:e1900042. doi:10.1002/pmic.201900042.
   PubMed Web of Science ®Google Scholar
• Lin Z, Wang Y, Lin S, Liu D, Mo G, Zhang H, Dou Y. Identification of potential biomarkers for abdominal pain in IBS patients by bioinformatics approach. BMC Gastroenterol. 2021;21:48. doi:10.1186/s12876-021-01626-7.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Zhernakova A, Bozzarelli I, D’amato M. Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies. Nat Rev Gastroenterol Hepatol. 2022;19:689–702. doi:10.1038/s41575-022-00662-2.
   PubMed Web of Science ®Google Scholar
• Eijsbouts C, Zheng T, Kennedy NA, Bonfiglio F, Anderson CA, Moutsianas L, Holliday J, Shi J, Shringarpure S, Agee M, et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat Genet. 2021;53:1543–1552. doi:10.1038/s41588-021-00950-8.
   PubMed Web of Science ®Google Scholar
• Vollert J, Wang R, Regis S, Yetman H, Lembo AJ, Kaptchuk TJ, Cheng V, Nee J, Iturrino J, Loscalzo J, et al. Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome. Front Psychiatry. 2022;13:842030. doi:10.3389/fpsyt.2022.842030.
   PubMed Web of Science ®Google Scholar
• Zhang ZF, Duan ZJ, Wang LX, Yang D, Zhao G, Zhang L. The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies. BMC Gastroenterol. 2014;14:23. doi:10.1186/1471-230X-14-23.
   PubMed Web of Science ®Google Scholar
• Mahurkar-Joshi S, Chang L. Epigenetic Mechanisms in Irritable Bowel Syndrome. Front Psychiatry. 2020;11:805. doi:10.3389/fpsyt.2020.00805.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yang L, Larson S, Basra S, Merwat S, Tan A, Croce C, Verne GN. Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1. Gut. 2016;65:797–805. doi:10.1136/gutjnl-2013-306464.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Carlson P, Acosta A, Busciglio I, Nair AA, Gibbons SJ, Farrugia G, Klee EW. RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. Am J Physiol Gastrointest Liver Physiol. 2014;306:G1089–98. doi:10.1152/ajpgi.00068.2014.
   PubMed Web of Science ®Google Scholar
• Dussik CM, Hockley M, Grozic A, Kaneko I, Zhang L, Sabir MS, Park J, Wang J, Nickerson CA, Yale SH, et al. Gene Expression Profiling and Assessment of Vitamin D and Serotonin Pathway Variations in Patients with Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018;24:96–106. doi:10.5056/jnm17021.
   PubMed Web of Science ®Google Scholar
• Wiley JW, Higgins GA, Hong S. Chronic psychological stress alters gene expression in rat colon epithelial cells promoting chromatin remodeling, barrier dysfunction and inflammation. PeerJ. 2022;10:e13287. doi:10.7717/peerj.13287.
   PubMed Web of Science ®Google Scholar
• Gupta A, Cole S, Labus JS, Joshi S, Nguyen TJ, Kilpatrick LA, Tillisch K, Naliboff BD, Chang L, Mayer EA. Gene expression profiles in peripheral blood mononuclear cells correlate with salience network activity in chronic visceral pain: a pilot study. Neurogastroenterol Motil. 2017;29. doi:10.1111/nmo.13027.
   PubMed Web of Science ®Google Scholar
• Edwinson AL, Yang L, Peters S, Hanning N, Jeraldo P, Jagtap P, Simpson JB, Yang T-Y, Kumar P, Mehta S, et al. Gut microbial β-glucuronidases regulate host luminal proteases and are depleted in irritable bowel syndrome. Nat Microbiol. 2022;7:680–694. doi:10.1038/s41564-022-01103-1.
   PubMed Web of Science ®Google Scholar
• Jabbar KS, Dolan B, Eklund L, Wising C, Ermund A, Johansson Å, Törnblom H, Simren M, Hansson GC. Association between Brachyspira and irritable bowel syndrome with diarrhoea. Gut. 2021;70:1117–1129. doi:10.1136/gutjnl-2020-321466.
   PubMed Web of Science ®Google Scholar
• Priya S, Burns MB, Ward T, Mars RAT, Adamowicz B, Lock EF, Kashyap PC, Knights D, Blekhman R. Identification of shared and disease-specific host gene–microbiome associations across human diseases using multi-omic integration. Nat Microbiol. 2022;7:780–795. doi:10.1038/s41564-022-01121-z.
   PubMed Web of Science ®Google Scholar
• Sarnoff RP, Bhatt RR, Osadchiy V, Dong, T, Labus, JS, Kilpatrick, LA, Chen, Zixi, Subramanyam, V, Zhang, Y, Ellingson, BM, et al. A multi-omic brain gut microbiome signature differs between IBS subjects with different bowel habits. Neuropharmacology. 2023;225:109381. doi:10.1016/j.neuropharm.2022.109381.
   PubMed Web of Science ®Google Scholar
• Kumbhare SV, Francis-Lyon PA, Kachru D, Uday T, Irudayanathan C, Muthukumar KM, Ricchetti RR, Singh-Rambiritch S, Ugalde J, Dulai PS, et al. Digital therapeutics care utilizing genetic and gut microbiome signals for the management of functional gastrointestinal disorders: results from a preliminary retrospective study. Front Microbiol. 2022;13:826916. doi:10.3389/fmicb.2022.826916.
   PubMed Web of Science ®Google Scholar
• Llorens-Rico V, Simcock JA, Huys GRB, Raes J. Single-cell approaches in human microbiome research. Cell. 2022;185:2725–2738. doi:10.1016/j.cell.2022.06.040.
   PubMed Web of Science ®Google Scholar